MGN-3/Biobran, modified arabinoxylan from rice bran, sensitizes human breast cancer cells to chemotherapeutic agent, daunorubicin

Cancer Detect Prev. 2008;32(1):1-6. doi: 10.1016/j.cdp.2008.02.006. Epub 2008 Apr 11.


Background: MGN-3/Biobran, a modified form of arabinoxylan from rice bran, is a potent biological response modifier (BRM). Our previous studies demonstrated that MGN-3 sensitizes human leukemia cells to death receptor [CD95]-induced apoptosis [Ghoneum M, Gollapudi S. MGN-3 sensitizes human T cell leukemia cells to death receptor (CD95)-induced apoptosis. Cancer Lett 2003;201:41-9]. In this study, we evaluated the chemo-sensitizing activity of MGN-3 against human breast cancer cells (BCCs) in vitro.

Methods: BCCs (MCF-7 and HCC70 cells) were cultured with different concentrations of daunorubicin (DNR) (from 1x10(-9) to 1x10(-6)M) in the presence or absence of selected concentrations of MGN-3 (100-1000mug/ml) for 3 days. Cancer cell survival was determined by MTT assay and drug accumulation was determined by flow cytometry.

Results: Treatment with MGN-3 increased susceptibility of BCCs to DNR (5.5-fold for MCF-7 and 2.5-fold for HCC70 cells) as compared to BCCs treated with DNR alone. The sensitizing effect of MGN-3 was associated with increased accumulation of DNR in cancer cells.

Conclusions: Our data demonstrate that MGN-3 is an effective chemo-sensitizer and may represent a potential novel adjuvant for the treatment of breast cancer.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Cell Line, Tumor
  • Cell Survival
  • Chemotherapy, Adjuvant
  • Daunorubicin / pharmacokinetics
  • Daunorubicin / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Humans
  • Xylans / therapeutic use*


  • Antineoplastic Agents
  • Xylans
  • polysaccharide MGN3
  • Daunorubicin